- Home
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Club
- Mobile
- Trust Equitymaster
- Help
- Free Reports
-
Mobile App
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- TORRENT PHARMACEUTICALS LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
Torrent Pharma Quarterly Results 
(TORR)
Here are the latest quarterly results of Torrent Pharma. For more details, see the Torrent Pharma financial fact sheet and Torrent Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
Torrent Pharma Quarterly Results
| No. of Mths Qtr. Ending |
3
Sep-15* |
3
Dec-15* |
3
Mar-16* |
3
Jun-16* |
3
Sep-16* |
3
Dec-16* |
3
Mar-17* |
3
Jun-17* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 16,910 | 15,390 | 14,990 | 15,450 | 14,290 | 14,430 | 14,340 | 13,740 | |
| Other income | Rs m | 740 | 510 | 240 | 260 | 430 | 500 | 1,040 | 1,050 | |
| Turnover | Rs m | 17,650 | 15,900 | 15,230 | 15,710 | 14,720 | 14,930 | 15,380 | 14,790 | |
| Expenses | Rs m | 9,770 | 9,260 | 10,150 | 11,080 | 10,990 | 11,270 | 11,390 | 10,770 | |
| Gross profit | Rs m | 7,140 | 6,130 | 4,840 | 4,370 | 3,300 | 3,160 | 2,950 | 2,970 | |
| Depreciation | Rs m | 610 | 610 | 650 | 680 | 690 | 730 | 970 | 800 | |
| Interest | Rs m | 480 | 420 | 380 | 490 | 510 | 480 | 580 | 560 | |
| Profit before tax | Rs m | 6,790 | 5,610 | 4,050 | 3,460 | 2,530 | 2,450 | 2,440 | 2,660 | |
| Tax | Rs m | 1,640 | 780 | 480 | 540 | 460 | 160 | 380 | 780 | |
| Profit after tax | Rs m | 5,150 | 4,830 | 3,570 | 2,920 | 2,070 | 2,290 | 2,060 | 1,880 | |
| Gross profit margin | % | 42.2 | 39.8 | 32.3 | 28.3 | 23.1 | 21.9 | 20.6 | 21.6 | |
| Effective tax rate | % | 24.2 | 13.9 | 11.9 | 15.6 | 18.2 | 6.5 | 15.6 | 29.3 | |
| Net profit margin | % | 30.5 | 31.4 | 23.8 | 18.9 | 14.5 | 15.9 | 14.4 | 13.7 | |
| Diluted EPS | Rs | 30.4 | 28.5 | 21.1 | 17.3 | 12.2 | 13.5 | 12.2 | 11.1 | |
| Diluted EPS (TTM) | Rs | 74.5 | 93.2 | 106.6 | 97.3 | 79.1 | 64.1 | 55.2 | 49.0 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
More Pharmaceuticals Company Quarterly Results: WYETH LTD TTK HEALTHCARE ORCHID PHARMA LTD ALKEM LABORATORIES SUN PHARMA
Compare TORRENT PHARMA With: WYETH LTD TTK HEALTHCARE ORCHID PHARMA LTD ALKEM LABORATORIES SUN PHARMA
Compare TORRENT PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Elections in Germany, NTPC, PNB Share Price & Other Top Cues in Action Today(Pre-Open)
Indian share markets languished in red in previous session as rupee hit its weakest point since early April amid concerns that the government's plan for an impetus to halt an economic slowdown.
Views on news
Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)
Sep 22, 2017Muted growth in CRAMS segment continues to impact topline.
Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)
Aug 14, 2017A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)
Aug 14, 2017GST impact coupled with price erosion in US leads to lower profits for the quarter.
Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)
Aug 8, 2017Profits plunge due to higher raw material costs.
Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)
Jun 23, 2017Net Profit lower due to exceptional items in the previous year.
More Views on NewsMost Popular
Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)
Sep 16, 2017We take a glimpse of Equitymaster's results from rule based investing.
Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)
Sep 13, 2017Nifty is above 10,000 once again. Have you missed the bus?
Gold Imports Surge: Are People Hedging the Risk of Another Demonetisation?(Vivek Kaul's Diary)
Sep 19, 2017Imports of the yellow metal have surged big time this year.
Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments
Sep 18, 2017Welcome to a bold, new initiative designed for the truly contrarian investor.
A Little-Known Japanese Secret for Compounding Wealth
Sep 22, 2017What Warren Buffett and Benjamin Graham have in common with a little known Japanese secret.
More|
| |
TORRENT PHARMA SHARE PRICE
Sep 22, 2017 (Close)
TRACK TORRENT PHARMA
- Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON TORRENT PHARMA
TORRENT PHARMA 5-YR ANALYSIS
COMPARE TORRENT PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
